aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

aTyr Pharma (LIFE) reports robust Q4 earnings, advances lead candidate

aTyr Pharma (LIFE) is well-positioned with a strong financial standing, a focus on innovative drug development for inflammatory diseases, and ongoing clinical trials for lead candidate efzofitimod targeting ILD and pulmonary sarcoidosis. While facing challenges in addressing analyst inquiries, the company has opportunities to advance its pipeline and leverage its financial resources for future growth.

aTyr Pharma progresses efzofitimod for ILD treatment, eyes transformative growth

aTyr Pharma's strong performance in advancing efzofitimod, solid financial position, and focus on innovation position them well for future growth and success
While facing challenges in pivotal studies and program management, the company's opportunities in pipeline expansion and disruptive drug discovery set a positive trajectory

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 2023 Jefferies Healthcare Conference, which is scheduled to take place June 7 – 9, 2023, in New York, NY.

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference, which is scheduled to take place May 16 – 17, 2023, in New York, NY.

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Atyr Pharma (LIFE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.44 per share a year ago.

Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan.

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

Applied Therapeutics Inc

LSI Industries

Ondas Holdings

Cue Biopharma

Nu Holdings

Olaplex Holdings

Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear.

7 Hot Growth Stocks Poised to Triple in 2023

Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT. Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT.

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Relations & Corporate Communications Sanjay Shukla - President & Chief Executive Officer Jill Broadfoot - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Sara Nik - H.C. Wainwright Yale Jen - Laidlaw Operator Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma Fourth Quarter and Full Year 2022 Conference Call.

aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan.

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at two upcoming investor conferences scheduled to take place in March 2023.

aTyr Pharma to Present at March Investor Conferences

Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know

SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to an additional 15% of the shares sold in the public offering. All of the shares to be sold in the offering are to be sold by aTyr. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

aTyr Pharma Announces Commencement of Public Offering of Common Stock

Patent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of care. Patent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of care.

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Ashlee Dunston - Director, IR & Corporate Communications Sanjay Shukla - President & CEO Jill Broadfoot - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Hartaj Singh - Oppenheimer Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw & Co Sean Kim - Jones Trading Kumaraguru Raja - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen and welcome to aTyr Pharma's Third Quarter 2022 Conference Call.

aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates

First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment.

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences scheduled to take place in November and December 2022.

aTyr Pharma to Present at Upcoming Investor Conferences

Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the Jefferies London Healthcare Conference, which is scheduled to take place November 15 – 17, 2022, in London, U.K.

aTyr Pharma to Present at the Jefferies London Healthcare Conference

Collaboration aims to accelerate drug discovery and advance company's tRNA synthetase platform Collaboration aims to accelerate drug discovery and advance company's tRNA synthetase platform

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets

Compositions and methods patent covers antibodies targeting NRP2 which may have therapeutic applications in the areas of cancer and inflammation Compositions and methods patent covers antibodies targeting NRP2 which may have therapeutic applications in the areas of cancer and inflammation

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies

SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, which is scheduled to take place September 12 – 14, 2022, at the Lotte New York Palace Hotel in New York, NY.

aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Relations and Corporate Communications Sanjay Shukla - President & Chief Executive Officer Leslie Nangle - Vice President, Research Jill Broadfoot - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Joe Pantginis - H.C. Wainwright Hartaj Singh - Oppenheimer Yale Jen - Laidlaw & Co Operator Good afternoon, ladies and gentlemen and welcome to aTyr Pharma Second Quarter 2022 Conference Call.

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2022 Results - Earnings Call Transcript

First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis.

News for aTyr Pharma Stock (LIFE)